All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F15%3A10314959" target="_blank" >RIV/00216208:11110/15:10314959 - isvavai.cz</a>

  • Alternative codes found

    RIV/00064165:_____/15:10314959

  • Result on the web

    <a href="http://dx.doi.org/10.1183/13993003.00364-2015" target="_blank" >http://dx.doi.org/10.1183/13993003.00364-2015</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1183/13993003.00364-2015" target="_blank" >10.1183/13993003.00364-2015</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN

  • Original language description

    In SERAPHIN, a long-term, randomised, controlled trial (NCT00660179) in pulmonary arterial hypertension (PAH), macitentan significantly reduced the risk of morbidity/mortality and PAH-related death/hospitalisation. We evaluated disease progression and the effect of macitentan in treatment-nave incident and prevalent cohorts. Patients allocated to placebo, or macitentan 3 mg or 10 mg were classified by time from diagnosis to enrolment as incident (<= 6 months; n=110) or prevalent (>6 months; n=157). Therisk of morbidity/mortality and PAH-related death/hospitalisation was determined using Cox regression. The risk of morbidity/mortality (Kaplan-Meier estimates at month 12: 54.4% versus 26.7%; p=0.006) and PAH-related death/hospitalisation (Kaplan-Meier estimates at month 12: 47.3% versus 19.9%; p=0.006) were significantly higher for incident versus prevalent patients receiving placebo, respectively. There was no significant difference in the risk of all-cause death between incident and p

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    FA - Cardiovascular diseases including cardio-surgery

  • OECD FORD branch

Result continuities

  • Project

  • Continuities

    V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Others

  • Publication year

    2015

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    European Respiratory Journal

  • ISSN

    0903-1936

  • e-ISSN

  • Volume of the periodical

    46

  • Issue of the periodical within the volume

    6

  • Country of publishing house

    GB - UNITED KINGDOM

  • Number of pages

    10

  • Pages from-to

    1711-1720

  • UT code for WoS article

    000366948700025

  • EID of the result in the Scopus database

    2-s2.0-84949032805